10 results
DEFA14A
IMGN
Immunogen, Inc.
21 Dec 23
Additional proxy soliciting materials
3:54pm
mission. It is still early in the process and many details have yet to be worked out; so, the answer is unknown, but we are committed to sharing
DEFA14A
EX-99.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
www.abbvie.com/oncology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today
8-K
EX-99.1
IMGN
Immunogen, Inc.
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
www.abbvie.com/oncology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today
8-K
EX-99.1
IMGN
Immunogen, Inc.
6 Apr 23
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
6:35am
ELAHERE while progressing the development of its earlier-stage assets and delivering on its mission to offer more good days to patients," said Martin
8-K
EX-99.1
64815rhxf9yzkfdu4
30 Nov 21
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
10-K405
ct68fk6a 2afu77wu
28 Sep 99
Annual report (delinquent filer disclosure)
12:00am
- Prev
- 1
- Next